Spending on MedTech Steady at Six Percent of U.S. Health Expenditures: Medical technology prices continue their trend of consistently low growth, increasing at approximately one-third the rate of prices in the overall economy and one-fifth the rate of prices for other medical goods and services over a 23-year period, according to an updated study released today by the Advanced Medical Technology Association (AdvaMed).
Each year, thousands of Americans are diagnosed with some form of skin cancer. The Surgeon General’s Call to Action to prevent skin cancer is important especially during these hot summer months when many of us spend extra time in the sun.
Last year, antibiotic-resistant infections caused more than two million illnesses and 23,000 deaths in the U.S. alone, according to the Centers for Disease Control. About 70 percent of those antibiotic-resistant infections were caused by hospital-acquired infections.
Senator Seeks Transparency in Medical Device Pricing
A new report predicts that the global in vitro diagnostics market will grow to $74.7 billion by 2020 fueled by increased awareness and demand for equipment that speeds up accurate diagnosis.
The US Food and Drug Administration (FDA) plans to pour as much as $37.5 million into an initiative intended to improve the quality of clinical trials, the agency has announced.
The US Food and Drug Administration (FDA) has finalized its long sought-after guidance document on the use of its four expedited drug approval programs, including the recently instituted breakthrough product designation.
The total value of acquisitions in the medical device sector rose nearly 200% during the 1st quarter, with deal volume up more than 111% compared with Q1 2013, according to a PricewaterhouseCoopers report.
US and EU trade negotiators are reportedly hung-up over how—or if—to rely on the results of one another’s regulatory inspections of drug manufacturing facilities, threatening to derail part of the Trans-Atlantic Trade and Investment Partnership (TTIP), The Wall Street Journal reports.
SUMMARY: Public comments submitted to the US Food and Drug Administration (FDA) regarding its guidance documents are generally tame, referring to matters for preference or a need to clarify vague sections. But in the case of a recent response to a new guidance on distributing reprints of scientific and medical literature, one group’s message for FDA is a bit more confrontational: Make changes to the guidance—or else.